These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 39413830)
1. The Role of CAR T-Cell Therapy in Relapsed/Refractory Adult B-ALL. Othman T; Logan AC; Muffly L; Leonard J; Park J; Shah B; Aldoss I J Natl Compr Canc Netw; 2024 Oct; 22(8):. PubMed ID: 39413830 [TBL] [Abstract][Full Text] [Related]
2. Advances in chimeric antigen receptor T cells. Beyar-Katz O; Gill S Curr Opin Hematol; 2020 Nov; 27(6):368-377. PubMed ID: 32925186 [TBL] [Abstract][Full Text] [Related]
3. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes. Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914 [TBL] [Abstract][Full Text] [Related]
5. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes. Schultz L Front Immunol; 2020; 11():1985. PubMed ID: 32849662 [TBL] [Abstract][Full Text] [Related]
6. Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Badar T; Shah NN Curr Treat Options Oncol; 2020 Feb; 21(2):16. PubMed ID: 32025828 [TBL] [Abstract][Full Text] [Related]
7. Decitabine consolidation after CD19/CD22 CAR-T therapy as a novel maintenance treatment significantly improves survival outcomes in relapsed/refractory B-ALL patients. Li T; Cui Q; Liu S; Li Z; Cui W; Li M; Ma Y; Cao X; Zhu X; Kang L; Yu L; Wu D; Tang X Leuk Res; 2024 Oct; 145():107569. PubMed ID: 39208598 [TBL] [Abstract][Full Text] [Related]
8. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas. Levin A; Shah NN Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353 [TBL] [Abstract][Full Text] [Related]
9. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia. Gupta S; Kohorst M; Alkhateeb HB Eur J Haematol; 2024 Jan; 112(1):51-63. PubMed ID: 38105391 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view. Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184 [TBL] [Abstract][Full Text] [Related]
11. Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies. Al-Juhaishi T; Ahmed S Curr Hematol Malig Rep; 2021 Feb; 16(1):32-39. PubMed ID: 33630232 [TBL] [Abstract][Full Text] [Related]
12. The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. Cerrano M; Ruella M; Perales MA; Vitale C; Faraci DG; Giaccone L; Coscia M; Maloy M; Sanchez-Escamilla M; Elsabah H; Fadul A; Maffini E; Pittari G; Bruno B Front Immunol; 2020; 11():888. PubMed ID: 32477359 [TBL] [Abstract][Full Text] [Related]
14. Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Curran KJ; Margossian SP; Kernan NA; Silverman LB; Williams DA; Shukla N; Kobos R; Forlenza CJ; Steinherz P; Prockop S; Boulad F; Spitzer B; Cancio MI; Boelens JJ; Kung AL; Khakoo Y; Szenes V; Park JH; Sauter CS; Heller G; Wang X; Senechal B; O'Reilly RJ; Riviere I; Sadelain M; Brentjens RJ Blood; 2019 Dec; 134(26):2361-2368. PubMed ID: 31650176 [TBL] [Abstract][Full Text] [Related]
15. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy. Aldoss I; Shan H; Yang D; Clark MC; Al Malki M; Aribi A; Agrawal V; Sandhu K; Salhotra A; Pourhassan H; Koller P; Ali H; Artz A; Karras N; Pawlowska AB; Murphy L; Palmer J; Stein A; Marcucci G; Pullarkat V; Nakamura R; Forman SJ Transplant Cell Ther; 2024 Aug; 30(8):788.e1-788.e9. PubMed ID: 38876428 [TBL] [Abstract][Full Text] [Related]
16. Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Valecha GK; Ibrahim U; Ghanem S; Asti D; Atallah JP; Terjanian T Expert Rev Hematol; 2017 Sep; 10(9):783-799. PubMed ID: 28666090 [TBL] [Abstract][Full Text] [Related]
17. Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy in Children With Central Nervous System Leukemia. Zhang L; Zuo Y; Lu A; Wu J; Jia Y; Wang Y; Zhang L Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e410-e414. PubMed ID: 33526401 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. Westin JR; Kersten MJ; Salles G; Abramson JS; Schuster SJ; Locke FL; Andreadis C Am J Hematol; 2021 Oct; 96(10):1295-1312. PubMed ID: 34310745 [TBL] [Abstract][Full Text] [Related]
19. CD4 Pan Y; Wang H; An F; Wu F; Tao Q; Li Y; Ruan Y; Zhai Z Int Immunopharmacol; 2021 Jul; 96():107742. PubMed ID: 33984717 [TBL] [Abstract][Full Text] [Related]
20. CAR T-cells for relapsed B-cell ALL in adults. Gilbert JA Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915 [No Abstract] [Full Text] [Related] [Next] [New Search]